Nurix Therapeutics, Inc. NRIX
23.08
(0.57)
(2.41%)
as of 25 Sep
- Market cap
- $2.5B
- P/E
- 0.0×
Follow NRIX
| May '26 | Feb '26 | Nov '25 | Aug '25 | Older periods | |
|---|---|---|---|---|---|
| ROE | (80.30%) | (61.40%) | (49.63%) | (65.35%) |
+8 more TTM periods Free account |
| ROA | (60.57%) | (47.20%) | (38.96%) | (47.25%) | |
| ROIC | 0.00% | 0.00% | 0.00% | 0.00% | |
| Return on Tangible Assets | (84.40%) | (61.02%) | (48.72%) | (64.63%) | |
| Average Days of Receivables | 0.00 | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow per Share | (2.74) | (2.47) | (3.04) | (2.87) | |
| Free Cash Flow | (304.53) | (271.85) | (263.47) | (241.36) | |
| Capital Expenditures | (10.82) | (11.56) | (14.00) | (10.98) | |
| Piotroski F-Score | 1.00 | 1.00 | 3.00 | 3.00 | |
| Other line items | |||||
| Cash ROIC | (34.71%) | (25.48%) | (22.04%) | (28.76%) | |
| Accounts Receivable Turnover | 0.00 | 0.00 | 0.00 | 0.00 | |
| Accounts Payable Turnover | 0.00 | 0.00 | 0.00 | 0.00 | |
| Average Days of Payables | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | |
| Research and Development Expense of Revenue | 927.31% | 461.66% | 377.36% | 359.80% | |
| Selling, General and Administrative Expense of Revenue | 155.06% | 77.60% | 62.80% | 59.52% | |
| Share Based Compensation of Revenue | 107.84% | 53.84% | 45.21% | 44.67% | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating CF/Net income | 0.86 | 0.88 | 0.94 | 0.94 | |
| Depreciation/Fixed assets | 0.35 | 0.38 | 0.38 | 0.35 | |
| Capex/Depreciation | (1.56) | (1.41) | (1.64) | (1.52) | |
| Revenue per Share | 0.33 | 0.65 | 0.97 | 0.99 | |
| Operating CF per Share | (2.64) | (2.36) | (2.88) | (2.74) | |
| Capex per Share | (0.10) | (0.10) | (0.16) | (0.13) | |
| Capex to Sales | 0.29 | 0.16 | 0.17 | 0.13 | |
| Net Profit Margin | (928.44%) | (411.37%) | (314.90%) | (292.50%) |
Columns are period end dates